Research Projects & Grants

• A Double-Blind, Parallel, Placebo Controlled, Multiple Dose, 6-Month Study Assessing the Safety and Efficacy of Daily Subcutaneous Injections of Recombinant Human Ciliary Neurotrophic Factor (rhCNTF) in Patients With Amyotrophic Lateral Sclerosis (ALS), Role: PI, (08/1994 - 08/1995) Status: Completed
• Does the Outcome of Patients with Non-electrical Seizures (Pseudoseizures) Depend on Their Underlying DSM-III-R Diagnosis?, Role: Investigator, (06/1994 - 06/1995) Status: Completed
• Extension Study: Use of Motor Unit Number Estimates to Quantitate the Effectiveness and Localize the Site of Action of Recombinant Human Ciliary Neurotrophic Factor (rhCNTF) in Patients with Amyotrophic Lateral Sclerosis, Role: PI, (06/1994 - 06/1995) Status: Completed
• A Natural History Study of Patients with Amyotrophic Lateral Sclerosis Using the Tuft's Quantitative Neuromuscular Exam (TQNE), Role: PI, (01/1994 - 01/1995) Status: Completed

College/University

• All of Us Southern California Consortium, Role: Co-Investigator, University of California, Irvine, (05/2024 - 04/2025) Status: Closed

For Profit Organization

• A multicenter, open-label, pilot study of Lamotrigine as adjunctive therapy and monotherapy in patients with epilepsy and comorbid depressive symptoms (protocol # LAM40117), Role: Investigator, GlaxoSmithKline, (08/2003 - 08/2004) Status: Completed
• PNU-95666E: Double-blind, placebo-controlled, dose-response study of tolerability, safety, and efficacy in patients with Parkinson's disease (Protocol M/2760/0009, dated 21 April, 1999), Role: Investigator, Pharmacia, (04/2001 - 04/2002) Status: Completed
• The clomethizole acute stroke study in acute ischemic stroke (class-I): a double blind, parallel group, multinational, multicenter study of the efficacy and safety of i.v. clomethiazole compared to placebo in patients with acute ischemic stroke. Study code: SA-CMZ-0009 (Protocol dated 08/21/97 and Amendment No. 1 dated 06/23/98)., Role: PI, ASTRA (USA), (07/2000 - 07/2001) Status: Completed
• Titration to response: Analysis of individualized therapy study (TRAITS) Protocol Capss -048, Role: PI, Ortho-McNeil Pharmaceutical, (06/1999 - 06/2000) Status: Completed
• Open-label study to identify the reasons for TASMAR dosage regimen changes in fluctuating Parkinson's disease patients, with follow-up extension, Role: Investigator, Hoffmann-La Roche Inc., (08/1998 - 08/1999) Status: Completed
• A phase III, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the safety and efficacy of a 24-hr infusion of Cervene in patients with acute ischemic stroke, Role: PI, Baker Norton Pharmaceuticals, (06/1997 - 06/1998) Status: Completed
• A Trial of Recombinant Methionyl Human Brain-Derived Neurotrophic Factor (r-metHuBDNF) Given by Daily Subcutaneous Injection to Patients with Amyotrophic Lateral Sclerosis (ALS), Role: PI, Amgen, Inc., (07/1996 - 07/1997) Status: Completed
• A Randomized, Triple-Blind, Placebo-Controlled, Outpatient Study to Examine the Safety and Efficacy of 10 mg p.o. MK-462 in the Treatment of Multiple Attacks of Migraine Headache, Role: PI, Merck, Sharp, and Dohme (MSD) Research Foundation, (04/1996 - 04/1997) Status: Completed
• A Randomized, Triple Blind, Placebo-Controlled, Outpatient Study to Examine the Safety and Efficacy of 10 mg p.o. MK-0462 in the Treatment of Multiple Attacks of Migraine Headache (Preliminary), Role: PI, Merck, Sharp, and Dohme (MSD) Research Foundation, (03/1996 - 03/1997) Status: Completed
• Clinical experience and use of sabril in patients with partial seizures, Role: PI, Marion Merrell Dow, (01/1996 - 01/1997) Status: Completed
• A Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Gabapentin in Patients with Amyotrophic Lateral Sclerosis (ALS), Role: PI, Warner Lambert, (10/1995 - 10/1996) Status: Completed
• A Trial of Recombinant Methionyl Human Brain-Derived Neurotrophic Factor (r-metHuBDNF)Given by Daily Subcutaneous Injection to Patients with Amyotrophic Lateral Sclerosis (ALS). [Advertising Stage], Role: PI, Amgen, Inc., (07/1995 - 07/1996) Status: Completed
• The BETASERON Patient Experience Study, Role: Investigator, National Medical Research Corp., (06/1995 - 06/1996) Status: Completed
• A multicenter, double-blind, placebo-controlled study of the tolerability and effect of entacapone in parkinson's subjects with end-of dose wearing off symptoms occuring no earlier than 4 hours after their most recent levodopa/carbidopa dose., Role: Investigator, Novartis Pharma AG, Status: Completed
• A double-blind, controlled, multicenter phase 2/3 study to assess the safety and efficacy of AVP-923 (dextromethorphan/quinidine) in the treatment of pseudobulbar affect in patients with amyotrophic lateral sclerosis, Role: PI, AVANIR Pharmaceuticals, Status: Completed
• A prospective, randomized, placebo-controlled, parallel group study of the continued efficacy and safety of subcutaneous injections of apomorphine in the treatment of "off" episodes in patients with "on/off" or "wearing-off" effects associated with late-stage Parkinson's disease after apomorphine use for at least a three month duration, Role: Investigator, Mylan Pharmaceuticals, Status: Completed
• A phase III, double-blind, placebo-controlled, randomized study comparing the efficacy safety, and tolerability of sumanirole versus placebo or ropinirole in patients with early Parkinson's disease (Protocol Number 666E-CNS-0075-021)., Role: Investigator, Pharmacia, Status: Completed

Internal

• Evaluating of linear estimates of disease progression as predictors of survival in patients with familial parkinsonism, Role: PI, LLU Dept. of Neurology, (05/2000) Status: Completed
• Clinical outcomes of patients who undergo electrodiagnostic testing for carpal tunnel syndrome, Role: PI, LLU Dept. of Neurology, (08/1999) Status: Completed
• Use of Motor Unit Number Estimates to Quantitate the Effectiveness and Localize the Site of Action of Recombinant Methionyl Human Brain Derived Neurotrophic Factor (BDNF) in Patients with Amyotrophic Lateral Sclerosis, Role: PI, LLU Dept. of Neurology, (11/1996 - 11/1997) Status: Completed
• A study of midodrine in patients with neurogenic orthostatic hypotension. Protocol #20.762-999A, Role: Investigator, LLU Dept. of Neurology, (07/1996 - 07/1997) Status: Completed